Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.3400 (-5.37%) ($6.3400 - $6.3400) on Mon. Oct. 4, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.25% (three month average) | RSI | 47 | Latest Price | $6.3400(-5.37%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -2.4% a day on average for past five trading days. | Weekly Trend | AUTL declines -1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(52%) ARKG(48%) IBUY(48%) IWO(48%) ARKK(47%) | Factors Impacting AUTL price | AUTL will decline at least -2.125% in a week (0% probabilities). VIXM(-34%) VXX(-30%) SHY(-21%) TLT(-19%) BNDX(-16%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.125% (StdDev 4.25%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-1.68(-126.5%) | Resistance Level | $6.69 | 5 Day Moving Average | $6.5(-2.46%) | 10 Day Moving Average | $6.55(-3.21%) | 20 Day Moving Average | $6.69(-5.23%) | To recent high | -14% | To recent low | 19.3% | Market Cap | $331m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |